NCT02944955View on ClinicalTrials.gov

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG

BLEX 404 Oral Liquid

"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."

All Listed Sponsors
lead

BioLite, Inc.

INDUSTRY